Background
==========

O-GlcNAcylation, or O-GlcNAc-ylation to distinguish it from acylation, is an O-linked glycosylation involving the β-attachment of a single N-acetylglucosamine (GlcNAc) to the serine (Ser)/threonine (Thr) residues catalyzed by O-GlcNAc transferase (OGT), whose removal is catalyzed by O-GlcNAcase (OGA) \[[@B1]\]. The two O-GlcNAc cycling enzymes OGT and OGA are each encoded by a single gene in mammalian species. Unlike N-linked or mucin-type O-linked glycosylation, O-GlcNAcylation occurs primarily in nucleocytoplasmic proteins \[[@B1]\]. Analogous to phosphorylation, the modification is dynamic and the O-GlcNAc moiety is not further extended \[[@B1]\]. O-GlcNAcylation is also often reciprocal to phosphorylation at the same or adjacent Ser/Thr residues \[[@B1]-[@B3]\], which led to a \"Yin-Yang\" hypothesis on protein functions modulated by the two post-translational modifications (PTMs) \[[@B4]\] through competitively blocking each other\'s occupancy at given sites. For example, reciprocal O-GlcNAcylation and phosphorylation at the same Ser16 of murine estrogen receptor β (ERβ modulate the degradation of ERβ by stabilizing or destabilizing the protein, respectively \[[@B5]\]. Similarly, O-GlcNAcylation of p53 at Ser149 is associated with decreased phosphorylation at the adjacent Thr155, resulting in decreased p53 ubiquitination and subsequent degradation, thus stabilizing p53 \[[@B6]\]. In contrast to the enormous body of research on phosphorylation, the amount of research on O-GlcNAcylation has been disproportionally small due to difficulties in detecting the O-GlcNAc group, partly because of its being labile, dynamic, and substoichiometric \[[@B7]\]. Over 600 proteins have been reported to be O-GlcNAcylated since it was first identified in 1984 \[[@B8]\], many of which were identified in recent years \[[@B1]-[@B3],[@B9]-[@B11]\] as a result of improved mass spectrometry technologies. Growing evidences now suggest that O-GlcNAcylation is very common and has broad roles in physiology and diseases, especially through its reciprocal interplay with phosphorylation, e.g., regulation of insulin signaling, transcription, and roles in diabetes and neurodegenerative diseases \[[@B2]\].

A number of bioinformatics databases have been developed for protein post-translational modifications, including those of general PTMs, e.g., dbPTM \[[@B12]\], or specific types, e.g., databases of protein phosphorylation, e.g., PhosphoELM \[[@B13]\], PhosphoSite \[[@B14]\], and those of protein glycosylation \[[@B15]\], ubiquitination \[[@B16]\] and protease cleavage \[[@B17]\]. By contrast, there has been no special database dedicated to O-GlcNAcylated proteins and sites, and their annotations are also scarce in protein databases, e.g., only \~100 experimental O-GlcNAcylation sites for 35 proteins are currently annotated in UniProtKB \[[@B18]\]. Moreover, O-GlcNAcylation annotations have not been included in the specialized glycosylation databases (e.g., GlycoBase, the Functional Glycomics Gateway) \[[@B15],[@B19]\].

Because of growing interests in studying the crucial roles of O-GlcNAcylation in cell signaling and many other cellular processes, identifying the site motifs and computationally predicting the O-GlcNAcylation sites become important bioinformatics tasks to assist those studies. Unlike N-linked glcycosylation with a consensus motif of \"Asn-X-Thr/Ser\", O-linked glycosylation, including mucin-type O-glycosylation and O-GlcNAc glycosylation, has not yet found well-defined sequence motifs. The past effort in developing prediction method for O-glycosylation has mostly focused on the mucin-type \[[@B20]-[@B23]\]. To our best knowledge there has been only one site prediction tool for O-GlcNAcylation, YinOYang, which is an artificial neural network system trained on sequence fragments of \~40 GlcNAcylation sites available at the time \[[@B24]\]. The motif of O-GlcNAcylation remains poorly defined, and there is a pressing need to develop an O-GlcNAcylation site prediction tool based on a much greater number of experimental O-GlcNAcylation sites available now.

Here we report the development of a [d]{.ul}ata[b]{.ul}ase of [O]{.ul}-[G]{.ul}lcN[A]{.ul}cylated [p]{.ul}roteins and sites (dbOGAP) for all currently known O-GlcNAcylated proteins reported from literature, and of an O-GlcNAcylation site prediction system (OGlcNAcScan) based on nearly 400 O-GlcNAcylation sites. Both the database and the prediction system are available through the dbOGAP web site, which serves as a public bioinformatics resource to facilitate research on O-GlcNAcylated proteins and to assist proteomic identification of O-GlcNAcylation sites.

Construction and Content
========================

1. The Database Development
---------------------------

The primary data source used for developing the dbOGAP database is literature about O-GlcNAcylated proteins published since O-GlcNAcylation was first discovered in early 1980\'s \[[@B8]\]. Figure [1](#F1){ref-type="fig"} depicts the overall workflow of the dbOGAP database and web site development. About 500 original and review articles were retrieved from PubMed (April 2010) that are related to protein O-GlcNAcylation and/or the O-GlcNAc cycling enzymes OGT and OGA. Abstracts and full-length articles were used to identify experimentally determined O-GlcNAcylated proteins and sites. The proteins were then mapped to UniProtKB entry records based on sequences and/or sequence identifiers (IDs) followed by manual verification. O-GlcNAcylated proteins and sites determined only from large-scale mass spectrometry (MS) without further validation using targeted MS and/or additional biochemical methods were annotated with evidence tags (e.g., \"LS: MALDI-TOF-MS\"). Orthologs of known O-GlcNAcylated proteins with identified O-GlcNAcylation sites were populated based on the HomoloGene groups \[[@B25]\] and/or BLAST neighbors \[[@B26]\], where the potential O-GlcNAcylation sites on the orthologs were inferred based on the conserved Ser/Thr residues. The experimental or inferred O-GlcNAcylation was attributed with literature (PubMed ID) or inference (from orthologs), respectively. A small number of currently annotated O-GlcNAcylated proteins in UniProtKB were also integrated into dbOGAP with the source attributed. Additional protein annotations, including other protein modifications (e.g., phosphorylation) and site features, Gene Ontology, pathways and disease information were integrated into dbOGAP from UniProtKB \[[@B18]\] or iProClass \[[@B27]\] databases.

![**Overall workflow of dbOGAP development**.](1471-2105-12-91-1){#F1}

2. The O-GlcNAc Site Prediction
-------------------------------

An O-GlcNAcylation site prediction system, OGlcNAcScan, was developed based on annotated O-GlcNAcylation sites in dbOGAP using the SVM^light^implementation of Support Vector Machine (SVM) \[[@B28]\]. A training data set of the prediction system consists of 373 positive instances that are experimental O-GlcNAcylation sites in 167 protein sequences from dbOGAP, and also of 29,897 negative instances that are the rest of the un-annotated Ser/Thr sites in the same protein sequences. Given a Ser/Thr site, *n*upstream and *n*downstream amino acids were regarded as its sequence context and then 2*n*+1 amino acids, including the O-GlcNAcylated Ser or Thr residue in the middle, were converted into a vector of binary values (0 or 1) using the widely-used *sparse encoding*method described, for example, in Julenius et al. 2005 \[[@B21]\]. Note, if the site is less than *n*amino acid away from the sequence terminals, the *end-of-sequence symbol*is padded at the terminal as many as needed to derive a fixed-length sequence fragment. In this encoding method, each amino acid type and the end-of-sequence symbol is coded with 21 binary values, e.g., 100\...0 (one followed by 20 zeros) for Ala, 010\...0 for Arg, \..., and 000\...1 for end-of-sequence), and the resulting feature vector consists of 21 × (2*n*+1) binary values. For different values of *n*, we trained SVM classifiers with the RBF kernel. The parameters involving these classifiers, *C*and *γ*, were optimized through 5-fold *cross-validation*tests, where classifiers were trained and tested, respectively, on a four-fifths and the remaining one-fifth of the data set for five times. We explored different sequence encoding methods, such as frequencies of amino acid types \[[@B21],[@B23]\] and gappy bi-grams/dimers \[[@B22]\], but the orthodox sparse encoding method with *n*= 5 yielded the best prediction performance.

3. The Database and the Web site Implementation
-----------------------------------------------

The dbOGAP database is implemented using the open source relational database management system, MySQL, with tables to store and manage the O-GlcNAcylation protein entries, O-GlcNAcylation sites from different sources and related literature information. The database is deployed on RedHat Enterprise Linux operating system (version 5.5). The Apache web server (version 2.2.15) (<http://httpd.apache.org/>) with the security enhanced module ModSecurity (version 2.5.10, <http://www.modsecurity.org/>), was deployed for the dbOGAP web site. All data query and retrieval from the dbOGAP web site is accomplished by scripts written in Perl, PHP and Javascript.

Utility
=======

1. The Database Contents
------------------------

The current version of dbOGAP contains 1163 entries, including 798 experimentally determined O-GlcNAcylated proteins (Figure [2](#F2){ref-type="fig"}, *Left*, A), and 365 proteins with inferred O-GlcNAcylation sites (total 735 sites) based on O-GlcNAcylated orthologs (Figure [2](#F2){ref-type="fig"}, *Left*, D). About 22% of all known O-GlcNAcylated proteins (172/798) have O-GlcNAcylation sites identified (404 sites), among which 140 proteins also have known phosphorylation sites (1581 sites) as well as 357 O-GlcNAcylation sites (Figure [2](#F2){ref-type="fig"}, *Left*, B, C). Interestingly, 48 of those 140 proteins have 122 Ser/Thr sites that are potentially Yin-Yang sites to be subjected to possible reciprocal regulation by O-GlcNAcylation and phosohorylation, including 42 identical sites and 74 non-identical sites that are within 4 amino acids away from each other (Table [1](#T1){ref-type="table"}). Overall, the number of currently identified O-GlcNAcylation sites is only \~11% (404/3687) of that of phosphorylation sites on all known O-GlcNAcylated proteins. Further, among all experimentally determined O-GlcNAcylated proteins, most (\~61%) are of humans, and other organisms include rat (19.7%), mouse (8%), fruit fly (6.7%), and African frog (3.1%) (Figure [2](#F2){ref-type="fig"}, *Right*).

![**Statistics of protein entries in dbOGAP.***Left*, Venn diagram showing the number of O-GlcNAcylated proteins and modification sites in the dbOGAP database. There are a total of 1163 protein entries in the database. A - Experimental O-GlcNAcylated proteins; B - Proteins with identified O-GlcNAcylation sites (G-sites); C - Proteins with identified phosphorylation sites (P-sites); D - Proteins with inferred O-GlcNAcylation sites based on orthologs with known O-GlcNAcylation sites. *Right*, Taxonomic distributions of experimentally determined O-GlcNAcylated proteins in dbOGAP. Numbers shown in the pie chart are percentage of proteins in given species over the total number of proteins in the database. \"Other\" species include *Bos taurus*(3 protein entries), *Gallus gallus*(2), *Coturnix coturnix japonica*(1), *Rhea americana*(1), *Macaca mulatta*(1) and Viruses (3).](1471-2105-12-91-2){#F2}

###### 

O-GlcNAcylation and phosphorylation occurring at identical or adjacent (+/- 4 amino acids) serine/threonine (S/T) sites of O-GlcNAcylated proteins.

  UniProt ID    Gene name   O-GlcNAcylation site                Identical phosphorylation S/T site   Adjacent phosphorylation S/T site
  ------------- ----------- ----------------------------------- ------------------------------------ ------------------------------------------
  RRP1B_HUMAN   RRP1B       S731                                S731                                 T728, S732, S735
                                                                                                     
  CARF_HUMAN    CDKN2AIP    S348                                                                     T345
                                                                                                     
  VIME_HUMAN    VIM         S7, T33, S34, S55                   S7, T33, S34, S55                    S5, S8, S9, S10, S29, T33, S34, S51, S56
                                                                                                     
  SPTB2_HUMAN   SPTBN1      S2324                                                                    T2328
                                                                                                     
  TPR_HUMAN     TPR         S1676                                                                    T1677
                                                                                                     
  RBP2_HUMAN    RANBP2      T1399                               T1399                                T1396, S1400
                                                                                                     
  H31_HUMAN     HIST1H3A    S11                                 S11                                  T12
                                                                                                     
  K2C8_HUMAN    KRT8        S13, S15                            S13                                  S9, S13, T14
                                                                                                     
  MYC_HUMAN     MYC         T58                                 T58                                  S62
                                                                                                     
  NUMA1_HUMAN   NUMA1       S1844                                                                    S1840, S1847
                                                                                                     
  PHB_HUMAN     PHB         T258                                                                     S254
                                                                                                     
  EMSY_HUMAN    EMSY        S236                                                                     S238
                                                                                                     
  NU214_HUMAN   NUP214      T1201, S1354                                                             T1203, S1356
                                                                                                     
  CRTC2_HUMAN   CRTC2       S70, S171, S173                     S70, S171                            T169, S171, T177
                                                                                                     
  KCC4_HUMAN    CAMK4       S356                                S356                                 S360
                                                                                                     
  FOXO1_HUMAN   FOXO1       T317                                                                     S319
                                                                                                     
  BPTF_HUMAN    BPTF        T2094                                                                    S2098
                                                                                                     
  HCFC1_HUMAN   HCFC1       T738                                T738                                 T737
                                                                                                     
  K1C18_HUMAN   KRT18       S30, S31, S49                       S30, S31                             S30, S31, S34, S47, S53
                                                                                                     
  P121A_HUMAN   POM121      T693                                                                     S697
                                                                                                     
  RBM14_HUMAN   RBM14       S244, S254, S256, S280              S256, S280                           S256
                                                                                                     
  AKT1_HUMAN    AKT1        T308, S473                          S473, T308                           
                                                                                                     
  ATX2L_HUMAN   ATXN2L      S684                                S684                                 
                                                                                                     
  SYUA_HUMAN    SNCA        S87                                 S87                                  
                                                                                                     
  IKKB_HUMAN    IKBKB       S733                                S733                                 
                                                                                                     
  ESR1_MOUSE    Esr1        S10                                 S10                                  T7
                                                                                                     
  SPTB2_MOUSE   Sptbn1      S2323                                                                    T2327
                                                                                                     
  BSN_MOUSE     Bsn         S1407, S2027, S2029, T2700, T2703   S2029, S2694, T2703                  T1406, S2029, T2703
                                                                                                     
  SYN1_MOUSE    Syn1        S518, T564                                                               S520, S568
                                                                                                     
  ABLM1_MOUSE   Ablim1      S496, S499                          S496, S499                           S494, T495, S496, S499, S502
                                                                                                     
  SKT_MOUSE     Skt         S357                                                                     S359, S361
                                                                                                     
  DEMA_MOUSE    Epb49       S285                                                                     S289
                                                                                                     
  RBM14_MOUSE   Rbm14       S278                                                                     S280
                                                                                                     
  CEBPB_MOUSE   Cebpb       S180, S181                                                               S184
                                                                                                     
  SRBS1_MOUSE   Sorbs1      S1199, S1200, S1201                 S1201                                S1201
                                                                                                     
  ESR2_MOUSE    Esr2        S61                                 S61                                  
                                                                                                     
  AKT1_MOUSE    Akt1        S473                                S473                                 
                                                                                                     
  NOS3_RAT      Nos3        S1178                                                                    T1174, S1176
                                                                                                     
  SP1_RAT       Sp1         S613, T641, S642, S699, S703        S613, T641, S642, S703               T641, S642, S703
                                                                                                     
  LBR_RAT       Lbr         S96                                                                      S99
                                                                                                     
  TAU_RAT       Mapt        S711                                S711                                 S707, T714, S715
                                                                                                     
  KPCB_RAT      Prkcb       T635                                T635                                 
                                                                                                     
  KPCD_RAT      Prkcd       T295, T348                          T295                                 S299
                                                                                                     
  KPCE_RAT      Prkce       S368, T710                          S368, T710                           
                                                                                                     
  KPCG_RAT      Prkcg       T689, S690                                                               S687
                                                                                                     
  SYN1_RAT      Syn1        S516, T562                                                               S518, S566
                                                                                                     
  G3P_RAT       Gapdh       T227                                T227                                 
                                                                                                     
  LT_SV40       SV40gp6     S111, S112                          S112                                 S112

### Functional profiles of O-GlcNAcylated proteins

We analyzed Gene Ontology (GO) profiles of currently known human O-GlcNAcylated proteins (\~490) using the DAVID tool \[[@B29]\]. We first examined the major enriched GO categories of O-GlcNAcylated proteins annotated with GO terms at higher levels of GO hierarchy (covering ≥10% of the proteins) (Table [2](#T2){ref-type="table"}). As shown by the GO *Cellular Components*profiling, O-GlcNAcylated proteins are mostly those of nucleoplasmic distribution, including membrane or non-membrane bounded organelles, cytosol, cytoskeleton, and nuclear compartments. The O-GlcNAcylated proteins mainly possess nucleotide and nucleic acid binding activities and transcription regulator activities (GO *Molecular Function*), and participate in transcriptional regulation, macromolecular complex assembly, intracellular transport, translation, regulation of cell cycle and apoptosis, and regulation of macromolecule metabolic process (GO *Biological Processes*).

###### 

Major GO categories of human O-GlcNAcylated proteins.

  Gene Ontology (GO) Terms                                             Count\*   \% Total   P-Value
  -------------------------------------------------------------------- --------- ---------- ----------
  **GO Biological Processes**                                                               
                                                                                            
  GO:0045449\~regulation of transcription                              108       23.48      5.90E-04
                                                                                            
  GO:0006350\~transcription                                            93        20.22      1.99E-04
                                                                                            
  GO:0051252\~regulation of RNA metabolic process                      75        16.30      6.09E-03
                                                                                            
  GO:0006355\~regulation of transcription, DNA-dependent               69        15.00      3.08E-02
                                                                                            
  GO:0043933\~macromolecular complex subunit organization              54        11.74      1.64E-09
                                                                                            
  GO:0065003\~macromolecular complex assembly                          53        11.52      4.68E-10
                                                                                            
  GO:0046907\~intracellular transport                                  52        11.30      8.96E-10
                                                                                            
  GO:0007049\~cell cycle                                               52        11.30      2.14E-07
                                                                                            
  GO:0006412\~translation                                              51        11.09      3.30E-21
                                                                                            
  GO:0006396\~RNA processing                                           51        11.09      4.00E-12
                                                                                            
  GO:0008104\~protein localization                                     51        11.09      1.91E-05
                                                                                            
  GO:0010605\~negative regulation of macromolecule metabolic process   48        10.43      1.39E-06
                                                                                            
  GO:0042981\~regulation of apoptosis                                  48        10.43      1.60E-05
                                                                                            
  GO:0043067\~regulation of programmed cell death                      48        10.43      2.07E-05
                                                                                            
  GO:0010941\~regulation of cell death                                 48        10.43      2.25E-05
                                                                                            
  GO:0045184\~establishment of protein localization                    47        10.22      1.11E-05
                                                                                            
  GO:0010604\~positive regulation of macromolecule metabolic process   47        10.22      1.55E-04
                                                                                            
  **GO Molecular Function**                                                                 
                                                                                            
  GO:0000166\~nucleotide binding                                       132       28.70      2.56E-13
                                                                                            
  GO:0003677\~DNA binding                                              101       21.96      7.11E-04
                                                                                            
  GO:0032555\~purine ribonucleotide binding                            92        20.00      7.02E-06
                                                                                            
  GO:0032553\~ribonucleotide binding                                   92        20.00      7.02E-06
                                                                                            
  GO:0017076\~purine nucleotide binding                                92        20.00      3.91E-05
                                                                                            
  GO:0030528\~transcription regulator activity                         83        18.04      6.87E-07
                                                                                            
  GO:0003723\~RNA binding                                              82        17.83      2.05E-24
                                                                                            
  GO:0001882\~nucleoside binding                                       82        17.83      1.56E-05
                                                                                            
  GO:0005524\~ATP binding                                              81        17.61      1.03E-06
                                                                                            
  GO:0032559\~adenyl ribonucleotide binding                            81        17.61      1.73E-06
                                                                                            
  GO:0030554\~adenyl nucleotide binding                                81        17.61      1.26E-05
                                                                                            
  GO:0001883\~purine nucleoside binding                                81        17.61      2.16E-05
                                                                                            
  GO:0005198\~structural molecule activity                             56        12.17      8.96E-12
                                                                                            
  GO:0042802\~identical protein binding                                51        11.09      3.27E-09
                                                                                            
  **GO Cellular Component**                                                                 
                                                                                            
  GO:0043232\~intracellular non-membrane-bounded organelle             170       36.96      6.37E-29
                                                                                            
  GO:0043228\~non-membrane-bounded organelle                           170       36.96      6.37E-29
                                                                                            
  GO:0005829\~cytosol                                                  141       30.65      7.16E-46
                                                                                            
  GO:0031974\~membrane-enclosed lumen                                  131       28.48      6.60E-24
                                                                                            
  GO:0043233\~organelle lumen                                          129       28.04      1.20E-23
                                                                                            
  GO:0070013\~intracellular organelle lumen                            128       27.83      5.00E-24
                                                                                            
  GO:0031981\~nuclear lumen                                            116       25.22      2.44E-25
                                                                                            
  GO:0005856\~cytoskeleton                                             77        16.74      2.21E-08
                                                                                            
  GO:0005654\~nucleoplasm                                              77        16.74      2.07E-18
                                                                                            
  GO:0030529\~ribonucleoprotein complex                                72        15.65      3.55E-29
                                                                                            
  GO:0005730\~nucleolus                                                55        11.96      3.09E-11
                                                                                            
  GO:0000267\~cell fraction                                            49        10.65      2.01E-03
                                                                                            
  GO:0044430\~cytoskeletal part                                        49        10.65      1.16E-04

\* The table is sorted based on counts of proteins annotated with given GO terms in each of the major GO category. The percentage of proteins with given GO terms over total number of human O-GlcNAcylated proteins is shown (% Total). A more detailed GO profiles are shown in \[Additional file [1](#S1){ref-type="supplementary-material"}, Supplementary Table S1\].

We further examined the O-GlcNAcylated proteins for enrichment of GO terms at deeper levels of the GO hierarchy. As summarized in \[Additional file [1](#S1){ref-type="supplementary-material"}, Supplementary Table S1\], the top enriched GO *biological processes*relate to protein translation, carbohydrate (glucose) metabolism, RNA processing/splicing, and RNA/protein transport, followed by macromolecular complex and organelle organization, regulation of cell cycle and cell death, chromosome organization and transcription, regulation of protein and other small molecule metabolisms. The enriched GO *molecular functions*include nucleoside, nucleotide and nucleic acid binding, transcription factor activity, protein binding and other molecular activities. The enriched GO *cellular components*include cytosol, organelle lumen and non-membrane-bounded organelles, nuclear compartments such as nucleoplasm, nuclear pore and nucleolus, ribosome and cytoskeleton, nuclear protein complexes and chromatin, membrane and vesicle associated spaces, and contractile associated proteins. Notably, although significant proportions of known O-GlcNAcylated proteins are associated with intracellular membranes or inner side of plasma membrane, only a few plasma transmembrane proteins, such as glucose transporters and notch receptor were reported to be O-GlcNAcylated \[[@B30]-[@B32]\]. Therefore O-GlcNAcylated proteins are primarily nucleocytoplasmic and are engaged in broad biological functions.

### Pathways and disease processes related to O-GlcNAcylated proteins

We examined pathway profiles of O-GlcNAcylated human proteins using GeneGO Pathway Maps \[[@B33]\]. A wide range of cellular pathways contain significant numbers of proteins that are known to be subjected to O-GlcNAcylation, including pathways involved in growth, development and differentiation, immune and inflammatory responses, cytoskeleton remodeling, and metabolic pathways such as gluconeogenesis. A total of 141 annotated GeneGO pathways are significantly enriched for the O-GlcNAcylated human proteins (p-value \< 1.0E-03). Table [3](#T3){ref-type="table"} lists 42 pathways that are enriched at a p-value of \<1.0E-05, many of which are growth factor signaling (e.g., EGFR, VEGF, TGFβ, and AKT) and cytokine signaling (e.g., GM-CSF, IL-2, IL6/7) pathways.

###### 

Pathway profiles using GeneGo Pathway Maps analysis.

  Pathways                                                                                      P-value    Count\*
  --------------------------------------------------------------------------------------------- ---------- ---------
  Development_Role of CDK5 in neuronal development                                              2.68E-11   12/34
                                                                                                           
  Development_Gastrin in cell growth and proliferation                                          3.86E-11   15/62
                                                                                                           
  Immune response_Gastrin in inflammatory response                                              2.00E-10   15/69
                                                                                                           
  Signal transduction_Activation of PKC via G-Protein coupled receptor                          5.21E-10   13/52
                                                                                                           
  Cytoskeleton remodeling_Cytoskeleton remodeling                                               9.88E-10   17/102
                                                                                                           
  Glycolysis and gluconeogenesis (short map)                                                    1.43E-09   14/67
                                                                                                           
  Cytoskeleton remodeling_Neurofilaments                                                        7.28E-09   9/25
                                                                                                           
  Transcription_Role of Akt in hypoxia induced HIF1 activation                                  1.59E-08   9/27
                                                                                                           
  Immune response_MIF - the neuroendocrine-macrophage connector                                 1.93E-08   11/46
                                                                                                           
  Development_Prolactin receptor signaling                                                      2.50E-08   12/58
                                                                                                           
  Cytoskeleton remodeling_TGF, WNT and cytoskeletal remodeling                                  2.72E-08   16/111
                                                                                                           
  Development_Gastrin in differentiation of the gastric mucosa                                  3.22E-08   10/38
                                                                                                           
  Development_GM-CSF signaling                                                                  4.94E-08   11/50
                                                                                                           
  Development_EGFR signaling pathway                                                            6.66E-08   12/63
                                                                                                           
  Cytoskeleton remodeling_Regulation of actin cytoskeleton by Rho GTPases                       7.06E-08   8/23
                                                                                                           
  G-protein signaling_Proinsulin C-peptide signaling                                            7.62E-08   11/52
                                                                                                           
  Development_Glucocorticoid receptor signaling                                                 1.04E-07   8/24
                                                                                                           
  Development_VEGF signaling and activation                                                     1.16E-07   10/43
                                                                                                           
  Cell adhesion_Histamine H1 receptor signaling in the interruption of cell barrier integrity   1.85E-07   10/45
                                                                                                           
  Immune response_Inhibitory action of Lipoxins on pro-inflammatory TNF-alpha signaling         1.85E-07   10/45
                                                                                                           
  Signal transduction_Calcium signaling                                                         1.85E-07   10/45
                                                                                                           
  Regulation of CFTR activity (norm and CF)                                                     2.50E-07   11/58
                                                                                                           
  Translation \_Regulation of translation initiation                                            2.92E-07   8/27
                                                                                                           
  Immune response_Histamine H1 receptor signaling in immune response                            3.53E-07   10/48
                                                                                                           
  Immune response_IL-2 activation and signaling pathway                                         4.34E-07   10/49
                                                                                                           
  Transcription_P53 signaling pathway                                                           5.48E-07   9/39
                                                                                                           
  Development_Slit-Robo signaling                                                               7.19E-07   8/30
                                                                                                           
  Development_Ligand-dependent activation of the ESR1/AP-1 pathway                              7.81E-07   6/14
                                                                                                           
  Development_PDGF signaling via STATs and NF-kB                                                1.24E-06   8/32
                                                                                                           
  Signal transduction_AKT signaling                                                             1.33E-06   9/43
                                                                                                           
  Development_VEGF signaling via VEGFR2 - generic cascades                                      2.00E-06   9/45
                                                                                                           
  Development_Thrombopoietin-regulated cell processes                                           2.00E-06   9/45
                                                                                                           
  Mucin expression in CF via IL-6, IL-17 signaling pathways                                     2.04E-06   8/34
                                                                                                           
  Development_TGF-beta-dependent induction of EMT via RhoA, PI3K and ILK.                       2.43E-06   9/46
                                                                                                           
  Development_PIP3 signaling in cardiac myocytes                                                2.93E-06   9/47
                                                                                                           
  Cytoskeleton remodeling_Keratin filaments                                                     3.24E-06   8/36
                                                                                                           
  Development_Thyroliberin signaling                                                            3.61E-06   10/61
                                                                                                           
  Development_A3 receptor signaling                                                             4.22E-06   9/49
                                                                                                           
  Transport_RAN regulation pathway                                                              4.42E-06   6/18
                                                                                                           
  Immune response_IL-7 signaling in T lymphocytes                                               5.01E-06   8/38
                                                                                                           
  Muscle contraction_Regulation of eNOS activity in endothelial cells                           5.66E-06   10/64
                                                                                                           
  Immune response_IL-6 signaling pathway                                                        7.57E-06   7/29

\*Number of known O-GlcNAcylated proteins over the total number of proteins annotated in the corresponding GeneGO pathways. The table is ranked based on the pathway enrichment P-values.

Because of the broad cellular processes and pathways that the O-GlcNAcylated proteins are known to participate in, O-GlcNAcylation may potentially play significant roles in many pathological conditions. Indeed, four categories of disease conditions have been implicated to involve O-GlcNAcylation, i.e., type II diabetes, neurodegenerative diseases, cardiovascular diseases, and cancers \[[@B34]\]. For example, OGT regulates insulin signaling through O-GlcNAcylation of several important insulin signaling molecules, e.g., IRS-1, PI3K, PDK1, and AKT1, leading to attenuation of insulin signaling responses in glycogen synthesis, activation of gluconeogenic genes and glucose transporter GLUT4 translocation, thus contributing to insulin resistance in type II diabetes \[[@B1],[@B35]\]. Tau protein is subject to both OGlcNAcylation and phosphorylation, and hyperphosphorylation apparently contributes to neurofibrillary tangle formation by tau in Alzheimer\'s disease \[[@B36]\]. O-GlcNAcylation represents a key regulatory mechanism in modulating vascular reactivity, such as contractile and relaxant response through modification of proteins, e.g., NOS, sarcoplasmic reticulumn Ca(2+)-ATPase, PKC, MAPK and cytoskeleton and microtubule proteins \[[@B37]\]. O-GlcNAcylation can mediate cardiac stress responses and has cardioprotective effects through transcription-mediated regulation as well as cardiomyocyte calcium homeostasis \[[@B38]\]. O-GlcNAcylation may have general roles in cancer through its involvement in oncogenesis or tumor suppression by coupling cellular metabolic status to regulation of signal transduction, transcription, and protein degradation. For example, reducing cellular UDP-GlcNAc level in MCF-7 cells changed the O-GlcNAcylation patterns of key proteins that control cell proliferation and differentiation, including Sp1, chaperonin TCP-1 theta, and oncogene Ets-related protein isoform 7 \[[@B39]\]. Many cancer genes or tumor suppressors are known to be O-GlcNAcylated or to interact with OGT, such as c-Myc, AKT1, AKT2, ATF1, CBP, FOXO1, TOP1, p53 and HIC1 \[[@B40]\]. In breast cancer cells, knockdown of OGT and the resulting global reduction of O-GlcNAcylation inhibited cell proliferation and metastasis ability \[[@B41]\].

2. The O-GlcNAcylation Site Prediction
--------------------------------------

Figure [3](#F3){ref-type="fig"} (*Above*) shows the graphical representation of sequence patterns surrounding the O-GlcNAcylation sites annotated in dbOGAP using the \"Two Sample Logo\" tool \[[@B42]\]. Enrichment of amino acids at -3/+2 position of the modified Ser/Thr, PPV([S/T]{.ul})TA, can be observed. However, the amino acid enrichment at each position independently is not sufficient for defining a sequence motif for O-GlcNAcylation sites. OGlcNAcScan was designed to exploit sequence properties through SVM for the site prediction. The system achieved an *area under ROC (the receiver operating characteristic) curve*(AUC) of 74.3% (Figure [3](#F3){ref-type="fig"}, *Below*) in a five-fold cross-validation test. AUC is a widely used performance measure of binary classifiers. A perfect classifier yields an AUC of 100% while random guessing yields that of 50%. Although the AUC value of OGlcNAcScan is relatively low, we need to consider at least the following two factors for its interpretation. First, the fraction of positive instances is extremely low in this task, i.e., 373 (1.23%) of 30270 Ser/Thr sites are annotated O-GlcNAcylation sites in dbOGAP. Some of the past studies on PTM site prediction reported the performance of prediction systems on a balanced data set, where sampled negative sites were used in the evaluation data set (e.g., the ratio of positive and negative sites were made to be 1:1 (50% positive) or 1:5 (16.7% positive)). In fact, the relative improvement of our trained SVM classifier, when compared to random guessing \[[@B43]\], can be as high as 14-fold (i.e., the *precision*of the classifier can be 14 times higher than the original rate of positives sites of 1.23%). The second factor to be considered is that negative instances in the evaluation data set may include not-yet-annotated true O-GlcNAcylation sites, which could have lowered the performance measures. We believe, however, sequence-based prediction of O-GlcNAcylation sites is inherently challenging. Additional training data through further annotation of proteins and sites as well as incorporation of other feature types, such as physiochemical properties of amino acids and protein structure information, may help improve the performance.

![**Sequence patterns and prediction performance of O-GlcNAcylation sites.***Above*, Graphical representation of sequence patterns surrounding the O-GlcNAcylation sites as determined by *Two Sample Logo*. The height of the amino acid character represents the relative frequency (enrichment or depletion) of the amino acid at any given positions relative to the O-GlcNAcylated residue (S/T at position \"0\"). *Below*, An ROC curve of OGlcNAcScan obtained in a five-fold cross-validation test. The area under this curve (i.e., AUC) is 74.3% of the plot area. The diagonal line indicates the ROC curve of random guessing, where the corresponding AUC value is 50%.](1471-2105-12-91-3){#F3}

3. The dbOGAP Web Site
----------------------

The dbOGAP web site provides two primary functionalities, search, query and browse of O-GlcNAcylated proteins and their related annotations, and *de novo*prediction of O-GlcNAcylation sites (Figure [4](#F4){ref-type="fig"}, \#1 and \#2). The dbOGAP database can be searched based on gene/protein names or identifiers, pathway names, or PubMed IDs. The protein entries can also be browsed based on gene names, organisms or pathways. The OGlcNAcScan site prediction system allows input of a protein sequence in FASTA format or a UniProtKB identifier (AC or ID) for site prediction. In addition, users can contribute their annotations to the database based on literature or from unpublished proteomic data on newly identified O-GlcNAcylation sites (Figure [4](#F4){ref-type="fig"}, \#3). All O-GlcNAcylation related literature citations are also available for browsing (Figure [4](#F4){ref-type="fig"}, \#4).

![**The dbOGAP website home page**. The website provides functionalities depicted by \#1-\#4: 1) search and browse the O-GlcNAcylated proteins in the database; 2) de novo prediction of O-GlcNAcylation sites for any protein sequences; 3) user annotation of O-GlcNAcylation information; 4) search and browse the total O-GlcNAcylation bibliography. The dbOGAP web site can be accessed at <http://cbsb.lombardi.georgetown.edu/OGAP.html>.](1471-2105-12-91-4){#F4}

### The O-GlcNAcylated protein entry

The dbOGAP protein entries are assigned unique IDs (e.g., OG00001) and are mapped to the corresponding UniProtKB IDs (1433B_HUMAN) and Accessions (P31946). The entry report provides detailed O-GlcNAcylation information and evidence attributions, including experimental and inferred O-GlcNAcylaytion data (Figure [5](#F5){ref-type="fig"}). O-GlcNAcylated residues and positions, as well as other modification sites (e.g., phosphorylation) and site features (e.g., binding sites), can be visualized in the context of protein sequences. The entry record also provides additional annotations such as GO, pathways (e.g., KEGG, PID and Reactome), protein-protein interactions (e.g., IntAct), protein families (e.g., Pfam) and diseases (OMIM), as well as additional protein bibliography integrated from UniProt and iProClass. Hyperlinks to source databases are provided for integrated annotations in dbOGAP entry records.

![**The dbOGAP protein entry view (shown is human AKT1)**. The entry report provides general protein information as well as specific O-GlcNAcylation information in the context of other posttranslational modifications and site features. The literature evidence (PMID) for the O-GlcNAc sites (e.g. S473 and T308) is given. Clicking on any site will display the residue in the neighboring sequence context (pointed by blue arrow). If the O-GlcNAcylation sites are inferred from orthologs with known sites (e.g. T308 of mouse AKT1, pointed by red arrow, inferred from human AKT1 shown in the inset), sequence alignment for the inferred sites can be displayed (lower portion of the inset). Other annotations are also included in the entry record (below the sequence section, not shown), including gene ontology, pathway, derived from UniProtKB and iProClass.](1471-2105-12-91-5){#F5}

### The O-GlcNAcScan report

The OGlcNAcScan report page provides a list of predicted O-GlcNAcylation sites for a given query sequence (Figure [6](#F6){ref-type="fig"}). The list can be sorted based on the prediction scores, positions of predicted sites, and the amino acids. The predicted site of interest can be highlighted in the protein sequence. The threshold for display of O-GlcNAcylation sites can be adjusted to increase or reduce the number of predictions. More detailed explanation and interpretation of the prediction results are provided in the online help document.

![**The O-GlcNAcylation site prediction result from OGlcNAcScan (shown is human ankyrin-1)**. The section at the bottom displays a ranked list of predicted O-GlcNAcylation sites (e.g., S1162 as the top one). The rank is based on the output value of the SVM classifier, which is converted into \"Estimated Precision\" and \"Lift\" scores (see help page linked from the top of the page for explanation). The estimated precision score is an estimated lower-bound of the precision (e.g., the score of 0.3910 indicates that at least 39.1% of sites assigned with the similar SVM output scores are O-GlcNAcylation sites), and the Lift score is an index of relative improvement through the classifier, which is calculated as the estimated precision divided by a constant value corresponding to the initial rate of positive sites (i.e., \~0.0123). All displayed potential sites are shown as red \"S/T\" in the sequence section (middle). Clicking on any predicted site, the residue will be highlighted in the sequence (arrow).](1471-2105-12-91-6){#F6}

### The dbOGAP database download

The dbOGAP web site provides a download page (Figure [4](#F4){ref-type="fig"}, linked in \#1) for downloading the database in several data files, including all O-GlcNAcylated proteins, sites and orthologs. A full bibliography of O-GlcNAcylated proteins can also be downloaded. The data sets for developing the OGlcNAcScan system are available to the scientific community for further development of the site prediction (Figure [4](#F4){ref-type="fig"}, \#2).

Discussion
==========

Up to now, the amount of data published on protein O-GlcNAcylation is only a fraction of that of phosphorylation, and its biological role is much less understood. Since 2006, the identification of O-GlcNAcylated proteins and sites has been rapidly growing due to the improved mass spectrometry technologies and O-GlcNAc enrichment techniques \[[@B7]-[@B9]\]. The dbOGAP database provides a timely bioinformatics resource to allow readily access by the community to the known and potential O-GlcNAcylated proteins and sites.

While a large number of O-GlcNAcylated proteins and sites were identified in recent years, many were determined based on large-scale mass spectrometry and would need to be further validated. Although O-GlcNAcylation has been known to occur primarily in nucleocytoplamic proteins, the GO profiles show that O-GlcNAcylated proteins are localized in a broad range of intracellular compartments. Interestingly, some O-GlcNAcylated proteins are of unusual classes, e.g., adenylate kinase 2 (AK2, UniProtKB: KAD2_HUMAN) \[[@B44]\] localized in the mitochondria inter-membrane space, and alpha-1-inhibitor 3 (A1i3, UniProtKB: A1I3_RAT) \[[@B45]\], a secreted protein. Although false positive identification of O-GlcNAcylation is not uncommon from mass spectrometry, it is possible that such proteins may be indeed O-GlcNAcylated. It is known that OGT has at least three isoforms differing in N-terminal sequences with identical catalytic domain, the mitochondrial (mOGT) and two nucleocytoplasmic forms (ncOGT and sOGT) \[[@B46],[@B47]\]. The mOGT form was shown associated with the mitochondrial inner membrane \[[@B46]\], thus consistent with the observation of O-GlcNAcylation of the mitochondrial protein AK2. There are a total of \~11 O-GlcNAcylated proteins in dbOGAP that are known to be secreted or have secreted forms besides cytoplasmic ones. It is possible that only the cytoplasmic forms of some of these proteins are O-GlcNAcylated while the secreted ones may not, albeit experimental validation is needed. Thus, the types and/or sources of O-GlcNAcylation identification have been assigned to protein entries as evidence attribution to annotations in the dbOGAP database.

The OGlcNAcScan site prediction system provides a much needed tool for studying protein glycosylation as well as phosphorylation. Since the site prediction is primarily based on the protein sequence context, some secreted proteins may be erroneously predicted even with a relatively high score, e.g., T298 in mucin 4 (UniProtKB: MUC4_HUMAN) predicted with a score of 0.287, though it is unlikely to be O-GlcNAcylated. In such cases, a cautionary note is given to indicate that a protein sequence being predicted is known to have \"secreted\" form(s). With the continuing growth of O-GlcNAcylation sites data, the OGlcNAcScan tool will be further enhanced through retraining the SVM model, as well as by integrating physiochemical properties and structural information into the SVM prediction model.

Conclusion
==========

In conclusion, the dbOGAP database and the web site become the first of its kind in the public domain to provide readily access to a curated and systematic collection of protein O-GlcNAcylation information, and to a state-of-the-art O-GlcNAcylation site prediction system, OGlcNAcScan, to assist proteomic identification of O-GlcNAc modification sites. Thus, the dbOGAP resource should benefit the biological community to study the broad roles of O-GlcNAcylation in physiology and diseases.

Availability and Requirements
=============================

The dbOGAP database and the OGlcNAcScan system can be publicly accessed at: <http://cbsb.lombardi.georgetown.edu/OGAP.html>. The database and related data sets can be downloaded at: <http://cbsb.lombardi.georgetown.edu/filedown.php>.
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###### Additional file 1

**Supplementary Table S1. Major categories of O-GlcNAcylated proteins based on GO terms at deeper level of GO hierarchy**. This table provides GO profiles at deeper level of GO terms to complement the major GO profiles of O-GlcNAcylated proteins in Table [2](#T2){ref-type="table"}.
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